Original Article

You have full text access to this OnlineOpen article

Relation of serum serotonin levels to bone density and structural parameters in women

  1. Ulrike I Mödder1,
  2. Sara J Achenbach2,
  3. Shreyasee Amin2,3,
  4. B Lawrence Riggs1,
  5. L Joseph Melton III2,
  6. Sundeep Khosla1,*

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090721

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 415–422, February 2010

Additional Information

How to Cite

Mödder, U. I., Achenbach, S. J., Amin, S., Riggs, B. L., Melton, L. J. and Khosla, S. (2010), Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res, 25: 415–422. doi: 10.1359/jbmr.090721

Author Information

  1. 1

    Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, MN, USA

  2. 2

    Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN, USA

  3. 3

    Division of Rheumatology, College of Medicine, Mayo Clinic, Rochester, MN, USA

*Endocrine Research Unit, Guggenheim 7-11A, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 6 JUL 2009
  4. Manuscript Revised: 7 MAY 2009
  5. Manuscript Received: 10 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

References

  • 1
    Yadav VK, Ryu J-H, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825–837.
  • 2
    Tamai K, Zeng X, Liu C, et al. A mechanism for WNT coreceptor activation. Mol Cell. 2004; 13: 149–156.
  • 3
    Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the Study of Osteoporotic Fractures. Arch Intern Med. 2007; 167: 1240–1245.
  • 4
    Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 167: 1246–1251.
  • 5
    Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007; 167: 188–194.
  • 6
    Bliziotes MM, Gunness M, Eshleman A, Wiren K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact. 2002; 2: 291–295.
  • 7
    Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005; 146: 685–693.
  • 8
    Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71: 266–274.
  • 9
    Colford JW, Lueddecke BA, Salvati M, et al. Immunoradiometric assay for intact human osteocalcin (I-49) without cross-reactivity to breakdown products. Clin Chem. 1999; 45: 526–531.
  • 10
    Power MJ, O'Dwyer B, Breen E, Fottrell PF. Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin Chem. 1991; 37: 281–284.
  • 11
    Melton LJ III, Looker AC, Shepherd JA, et al. Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int. 2005; 16: 1558–1564.
  • 12
    Riggs BL, Melton LJ III, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004; 19: 1945–1954 .
  • 13
    Camp JJ, Karwoski RA, Stacy MC, et al. A system for the analysis of whole-bone strength from helical CT images. Proc SPIE. 2004; 5369: 74–88.
  • 14
    Cann CE. Quantitative CT for determination of bone mineral density: a review. Radiology. 1988; 166: 509–522.
  • 15
    Kalender WA, Felsenberg D, Genant HK, Fischer M, Dequeker J, Reeve J. The European spine phantom: a tool for standardization and quality control in spinal bone mineral measurements by DXA and qCT. Eur J Radiol. 1995; 20: 83–92.
  • 16
    Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006; 21: 124–131.
  • 17
    Muller R, Hahn M, Vogel M, Delling G, Ruegsegger P. Morphometric analysis of noninvasively assessed bone biopsies: comparison of high-resolution computed tomography and histologic sections. Bone. 1996; 18: 215–220.
  • 18
    Laib A, Hilderbrand T, Hauselmann HJ, Ruegsegger P. Ridge number density: a parameter for in vivo bone structure analysis. Bone. 1997; 21: 541–546.
  • 19
    Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-qCT of the human forearm. Technol Health Care. 1998; 6: 329–337.
  • 20
    Laib A, Ruegsegger P. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone. 1999; 24: 35–39.
  • 21
    Parfitt AM, Mathews CHE, Villaneuva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest. 1983; 72: 1396–1409.
  • 22
    Jonnakuty C, Gragnoli C. What do we know about serotonin. J Cell Physiol, 2008; 217: 301–306.
  • 23
    Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediat Inflamm. 2002; 11: 211–21.
  • 24
    Izzati-Zade KF. The role of serotonin in the pathogenesis and clinical presentations of migraine attacks. Neurosci Behav Physiol. 2008; 38: 501–505.
  • 25
    Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M, Trypsinogen IV. Serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil. 2008; 20: 900–907.
  • 26
    Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004; 19: 1420–1431.
  • 27
    Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23: 1537–1551.
  • 28
    Blundell JE. Serotonin manipulations and the structure of feeding behaviour. Appetite 1986; 7: S39–S56.
  • 29
    Curzon G. Serotonin and appetite. Ann NY Acad Sci. 1990; 600: 521–530.
  • 30
    Leibowitz SF, Weiss GF, Suh JS. Medial hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behavior. Pharmacol Biochem Behav. 1990; 37: 735–742.
  • 31
    Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res. 1996; 73: 37–42.
  • 32
    McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes. 1990; 14: 361–372.
  • 33
    Pijl H, Koppeschaar HP, Willekens FL, Op de Kamp I, Veldhuis HD, Meinders AE. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes. 1991; 15: 237–242.
  • 34
    Lawton CL, Wales JK, Hill AJ, Blundell JE. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res. 1995; 3: 345–356.
  • 35
    Ward AS, Comer SD, Haney M, Fischman MW, Foltin RW. Fluoxetine-maintained obese humans: effect on food intake and body weight. Physiol Behav. 1999; 66: 815–821.
  • 36
    MacKenzie RG, Hoebel BG, Ducret RP, Trulson ME. Hyperphagia following intraventricular p-chlorophenylalanine-, leucine- or tryptophan-methyl esters: lack of correlation with whole brain serotonin levels. Pharmacol Biochem Behav. 1979; 10: 951–955.
View Full Article (HTML) Get PDF (101K)